STOCK TITAN

Hypha Labs Financials

FUNI
Source SEC Filings (10-K/10-Q) Updated Feb 17, 2026 Currency USD FYE September

This page shows Hypha Labs (FUNI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak
1/9

Hypha Labs passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality
0.12x

For every $1 of reported earnings, Hypha Labs generates $0.12 in operating cash flow (-$380K OCF vs -$3.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk
-28.3x

Hypha Labs earns $-28.3 in operating income for every $1 of interest expense (-$3.0M vs $106K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
-$3.0M
YoY-63.7%

Hypha Labs's EBITDA was -$3.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 63.7% from the prior year.

Net Income
-$3.1M
YoY-294.9%

Hypha Labs reported -$3.1M in net income in fiscal year 2025. This represents a decrease of 294.9% from the prior year.

EPS (Diluted)
$-0.02
YoY-100.0%

Hypha Labs earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
-$413K
YoY+61.1%

Hypha Labs generated -$413K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.1% from the prior year.

Cash & Debt
$38K
YoY-58.2%
5Y CAGR-14.4%
10Y CAGR-22.4%

Hypha Labs held $38K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
145M
YoY+17.9%
5Y CAGR+20.0%
10Y CAGR+26.6%

Hypha Labs had 145M shares outstanding in fiscal year 2025. This represents an increase of 17.9% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
$33K
YoY+19.2%
5Y CAGR-25.2%
10Y CAGR-31.5%

Hypha Labs invested $33K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 19.2% from the prior year.

FUNI Income Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $186K0.0% $186K N/A $82K+24.8% $65K-93.8% $1.1M N/A $486K
Operating Income $475K+200.0% -$475K N/A -$536K+19.9% -$669K+48.7% -$1.3M N/A -$614K
Interest Expense $6K-88.2% $47K N/A $26K+14.7% $23K+1.3% $22K N/A $22K
Income Tax N/A N/A N/A N/A N/A N/A N/A -$23K
Net Income $522K+200.0% -$522K N/A -$562K+12.4% -$642K+52.1% -$1.3M N/A -$707K
EPS (Diluted) $0.00 $0.00 N/A $0.00+100.0% $-0.010.0% $-0.01 N/A $-0.01

FUNI Balance Sheet

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Total Assets N/A $392K-4.3% $409K-9.9% $454K+76.7% $257K-0.6% $259K-47.6% $494K-34.4% $752K
Current Assets N/A $315K-1.9% $321K-5.8% $340K+82.1% $187K+5.2% $178K-56.7% $410K-44.2% $735K
Cash & Equivalents N/A $43K+12.4% $38K-74.1% $147K+597.8% $21K-42.3% $37K-59.9% $91K-82.1% $509K
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities N/A $3.1M+8.1% $2.8M+12.9% $2.5M+21.5% $2.1M+13.8% $1.8M+3.9% $1.8M+0.6% $1.7M
Current Liabilities N/A $1.3M+18.0% $1.1M-48.8% $2.2M+26.1% $1.7M+17.7% $1.5M+5.7% $1.4M-1.1% $1.4M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity N/A -$2.7M-10.2% -$2.4M-17.9% -$2.1M-13.7% -$1.8M-16.2% -$1.6M-24.1% -$1.3M-27.2% -$990K
Retained Earnings N/A -$24.2M-2.2% -$23.6M-2.4% -$23.1M-2.5% -$22.5M-2.9% -$21.9M-6.5% -$20.5M-2.3% -$20.1M

FUNI Cash Flow Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Operating Cash Flow $150K+200.0% -$150K+52.3% -$315K-1252.1% -$23K+30.8% -$34K-323.3% -$8K+98.2% -$436K+18.8% -$537K
Capital Expenditures $2K N/A $31K $0+100.0% -$1-100.1% $2K-83.0% $10K N/A
Free Cash Flow $149K N/A -$346K-1386.2% -$23K+30.8% -$34K-247.6% -$10K+97.8% -$446K N/A
Investing Cash Flow $2K N/A -$31K $0-100.0% $1+100.1% -$2K-103.6% $48K+374.7% -$17K
Financing Cash Flow $155K0.0% $155K-34.7% $237K+58.8% $149K+722.3% $18K+140.5% -$45K-49.7% -$30K $0
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

FUNI Financial Ratios

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets N/A -133.2% N/A -123.8%+126.0pp -249.8%+268.2pp -518.0% N/A -94.0%
Current Ratio N/A 0.24-0.0 0.29+0.1 0.16+0.0 0.11-0.0 0.12-0.2 0.29-0.2 0.52
Debt-to-Equity N/A -1.15+0.0 -1.17+0.1 -1.22-0.1 -1.14+0.0 -1.17+0.2 -1.39+0.4 -1.76
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$2.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.29), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Frequently Asked Questions

No, Hypha Labs (FUNI) reported a net income of -$3.1M in fiscal year 2025.

Hypha Labs (FUNI) reported diluted earnings per share of $-0.02 for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hypha Labs (FUNI) had EBITDA of -$3.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Hypha Labs (FUNI) generated -$413K in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Hypha Labs (FUNI) generated -$380K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Hypha Labs (FUNI) had $409K in total assets as of fiscal year 2025, including both current and long-term assets.

Hypha Labs (FUNI) invested $33K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Hypha Labs (FUNI) had 145M shares outstanding as of fiscal year 2025.

Hypha Labs (FUNI) had a current ratio of 0.29 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Hypha Labs (FUNI) had a debt-to-equity ratio of -1.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Hypha Labs (FUNI) had a return on assets of -758.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Hypha Labs (FUNI) had $38K in cash against an annual operating cash burn of $380K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Hypha Labs (FUNI) has negative shareholder equity of -$2.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Hypha Labs (FUNI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Hypha Labs (FUNI) has an earnings quality ratio of 0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Hypha Labs (FUNI) has an interest coverage ratio of -28.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top